Laddar...
Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials
BACKGROUND: Progression-free survival (PFS) exhibits suboptimal performance as the surrogate endpoint for overall survival (OS) in trials studying immune checkpoint inhibitors (ICIs). Here we propose a novel surrogate endpoint, modified PFS (mPFS), which omits the events of disease progression (but...
Sparad:
| I publikationen: | J Immunother Cancer |
|---|---|
| Huvudupphovsmän: | , , , , , , , |
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Publicerad: |
BMJ Publishing Group
2021
|
| Ämnen: | |
| Länkar: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8021890/ https://ncbi.nlm.nih.gov/pubmed/33795385 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/jitc-2020-002114 |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|